Valeant Pharmaceuticals "With all the bloviating on the campaign trail about reeling in drug costs these days, it’s safe to say the pharmaceutical industry is under siege.""But it’s not all the politicians’ fault; many of the sector’s injuries are self-inflicted. Case in point: Valeant Pharmaceuticals’ (VRX), whose stock has plunged 62% amid ongoing accounting concerns." As we see from the chart - VRX weekly price is on bearish breakdown: ...
This article is directed to the individual investor concerned with achieving the highest possible total return. The highest total return will typically come from a true growth stock simply because a faster growing company is worth more than a slower growing company past, present and future. On the other hand, for that statement to be true, a high rate of earnings growth must be consistently achieved. Generating and sustaining a high rate of earnings growth is the tricky part, because although there ...
In an interview with Kitco News, Harry Tchilinguirian, global head of commodity markets strategy at BNP Paribas, said that the bank is in no hurry to change its forecast and there is still a possibility for gold to drop below $1,000 an ounce. In January, the firm said that it expects gold prices to average $980 an ounce this year and $860 in 2017; and, Tchilinguirian said that fundamentally nothing has changed. In fact, the ...
The Dow Jones Industrial Average ended Friday with a decline of 5.9% year-to-date and still in correction territory 10.7% below its all-time high of 18,351.36 set on May 19. The Dow is up 6.1% since setting its 2016 low of 15,450.56 on Jan. 20. Only one of the eight “Dogs of the Dow” is lagging the Dow since setting their 2016 lows and five have gains between 13.8% and 16.1%. Four of the eight have gains year–to-date led by Verizon, with ...
Apple Inc. (NASDAQ:AAPL) is currently down almost 10% year to date, although it remains a favorite of both hedge funds and professional money managers. Most frighteningly, a steep decline after a disappointing quarter of relatively low iPhone sales growth has encouraged significant investor caution. more...
Recent Visitors
Archive
Go to Profile
Mark as Read